Floatz logo

htd1801

Type 2 Diabetes

HighTide Biopharma Pty LtdPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
73/ 100

Competitive context

141 Active assets in the Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

htd1801 is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
62 / 100
View asset →
primary sclerosing cholangitisDormant
B
Indicative ·
61 / 100
View asset →
digestive system disorderDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →